Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID‐19: A multicenter study

Abstract

BACKGROUND: To the authors' knowledge, little is known regarding the association between recent oncologic treatment and mortality in patients with cancer who are infected with coronavirus disease 2019 (COVID-19). The objective of the current study was to determine whether recent oncologic treatment is associated with a higher risk of death among patients with carcinoma who are hospitalized with COVID-19. METHODS: Data regarding 248 consecutive patients with carcinoma who were hospitalized with COVID-19 were collected retrospectively from 33 hospitals in Hubei Province, China, from January 1, 2020, to March 25, 2020. The follow-up cutoff date was July 22, 2020. Univariable and multivariable logistic regression analyses were performed to identify variables associated with a higher risk of death. RESULTS: Of the 248 patients enrolled, the median age was 63 years and 128 patients (52%) were male. On admission, 147 patients (59%) did not undergo recent oncologic treatment, whereas 32 patients (13%), 25 patients (10%), 12 patients (5%), and 10 patients (4%), respectively, underwent chemotherapy, surgery, targeted therapy, and radiotherapy. At the time of last follow-up, 51 patients (21%) were critically ill during hospitalization, 40 of whom had died. Compared with patients without receipt of recent oncologic treatment, the mortality rate of patients who recently received oncologic treatment was significantly higher (24.8% vs 10.2%; hazard ratio, 2.010 [95% CI, 1.079-3.747; P = .027]). After controlling for confounders, recent receipt of chemotherapy (odds ratio [OR], 7.495;

Clinical Characteristics of Cancer Patients With COVID-19: A Retrospective Multicentric Study in 19 Hospitals Within Hubei, China

“…In the previse study, Yekedüz E reported chemotherapy increased the risk of death from COVID-19 in cancer patients, but there was no safety concern for immunotherapy, targeted therapies, surgery and radiotherapy (25). Song K demonstrated a possible association between recent receipt of oncologic treatment and a higher risk of death among patients with carcinoma who are hospitalized with COVID-19 (26). However, the findings of the current study do not support the previous research (19,25).…”

Common contributing factors to COVID-19 and inflammatory bowel disease

“…COV: “The results of the current study demonstrated a possible association between recent receipt of oncologic treatment and a higher risk of death among patients with carcinoma who are hospitalized with COVID-19.” [ 122 ]…”

Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer

“…Although the American College of Chest Physicians guidelines emphasize treatment of an acute pulmonary embolism as soon as possible, using parenteral anticoagulants, such as subcutaneous low-molecular-weight heparin (LMWH) [ 3 ], the exact therapeutic dose and side effects monitoring remain uncertain [ 4 ]. COVID-19 have severely impacted care services of fragile groups, and in particular cancer patients, with a significant reduction in the intensity and quality of care [ 5 , 6 , 7 ] and also a reduced life expectancy if infected by SARS-CoV2 [ 8 ]. Neoplastic patients have a state of basic hypercoagulability which exposes them to greater risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) [ 9 , 10 , 11 ], even if not immediately manifested.…”